A new trading data show Halozyme Therapeutics Inc. (HALO) is showing positive returns.

With 0.94 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.72 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $35.62 whereas the lowest price it dropped to was $34.88. The 52-week range on HALO shows that it touched its highest point at $51.45 and its lowest point at $29.85 during that stretch. It currently has a 1-year price target of $47.78. Beta for the stock currently stands at 1.22.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HALO was up-trending over the past week, with a rise of 5.37%, but this was up by 2.48% over a month. Three-month performance dropped to -3.43% while six-month performance fell -19.40%. The stock lost -29.47% in the past year, while it has lost -3.98% so far this year. A look at the trailing 12-month EPS for HALO yields 1.87 with Next year EPS estimates of 3.42. For the next quarter, that number is 0.77. This implies an EPS growth rate of 77.88% for this year and 33.32% for next year. EPS is expected to grow by 21.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 26.15%.

Float and Shares Shorts:

At present, 135.15 million HALO shares are outstanding with a float of 130.79 million shares on hand for trading. On Jan 31, 2024, short shares totaled 7.64 million, which was 5.78% higher than short shares on Dec 29, 2023. In addition to Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. as the firm’s President, CEO & Director, Ms. Nicole LaBrosse serves as its Senior VP & CFO.

Institutional Ownership:

Through their ownership of 96.49% of HALO’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HALO since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With HALO analysts setting a high price target of $72.00 and a low target of $28.00, the average target price over the next 12 months is $47.78. Based on these targets, HALO could surge 102.87% to reach the target high and fall by -21.1% to reach the target low. Reaching the average price target will result in a growth of 34.63% from current levels.

Summary of Insider Activity:

Insiders traded HALO stock several times over the past three months with 3 Buys and 3 Sells. In these transactions, 20,000 shares were bought while 20,000 shares were sold. The number of buy transactions has increased to 42 while that of sell transactions has risen to 38 over the past year. The total number of shares bought during that period was 369,518 while 308,803 shares were sold.